From Monotherapy to Multi-Drug Regimens: Metformin's Role as the Therapeutic Backbone for Over Seven Decades

For over six decades, metformin has remained the cornerstone of T2DM management as monotherapy and in combination with other glucose-lowering drugs. As a part of treatment regimen, metformin significantly delays disease progression and complications, establishing itself as the therapeutic backbone in gluco-metabolic journey of T2D care. 1,2

Why Does Metformin Hold an Integral Place in T2D Care Continuum?

Metformin remains foundational across major guidelines. The ADA 2026 Standards of Care recognize metformin consideration as integral, safe at eGFR ≥30 mL/min/1.73 m², and backbone to combination therapy as T2DM progresses. The AACE 2026 Algorithm highlights its low hypoglycaemia risk and recommends metformin as monotherapy and when additional HbA1c reduction is needed following comorbidity-directed therapy, with early dual therapy at HbA1c ≥7.5%. The RSSDI consensus extends the role of metformin to high-risk younger individuals with prediabetes and overweight or obesity. 3,4,5

Metformin as Monotherapy in T2D: How is it the Backbone of Pharmacological Care?

Metformin monotherapy is recommended in T2D when HbA1c is <7.5%. It is noteworthy that approximately 20% of recently diagnosed Indian T2DM patients fall in this range. In uncontrolled T2D, as an independent add-on with dual or triple agent FDC regimens, metformin suppresses hepatic glucose output, enables divided dose up-titration for optimal GI tolerance, mitigates hypoglycaemia risk, and offers cost advantage. In T2DM with NAFLD, metformin ameliorates insulin resistance, reduces hepatic steatosis, and improves fasting blood glucose levels. More recently, concurrent initiation of metformin with GLP-1 receptor agonists led to a synergistic weight loss response maintained over 12 months in real-world experience. 4,6,7,8

How Does Metformin Complement Every Class of Glucose-Lowering Drugs as Monotherapy & Add-On?

Metformin serves as the pharmacological anchor upon which successive agents are layered.

Metformin Pairing with Other Agents	Evidence for Relevance in Clinical Care
SGLT2 inhibitors	Adds cardiorenal protection; clinical trial data demonstrate a 30% reduction in kidney disease progression (HR 0.70) and a 38% reduction in cardiovascular death (HR 0.62). 9,10
DPP-4 inhibitors	Preserve endogenous incretin activity while enhancing insulin sensitivity through distinct pathways, the combination lowers HbA1c by up to 2.1% versus monotherapy, without hypoglycaemia or weight gain. 11
Insulin	Reduces exogenous insulin dose requirement by 29% and mitigates weight gain (0.4 kg versus 2.3 kg with insulin alone). 12
GLP-1 receptor agonists / GLP-1/GIP twin agonists	Reduces HbA1c by 1.6% and body weight by 6.1 kg; GLP-1/GIP twin agonists achieve HbA1c reduction of 2.0% and weight loss of 8.5 kg with metformin as background therapy. 6,13
Alpha-glucosidase inhibitors	Addresses fasting and postprandial glucose; FDC reduced HbA1c by 1.0%, fasting glucose by 42 mg/dL, and postprandial glucose by 80 mg/dL reported in Indian patients. 14
Glinides	Supports prandial glucose control complemented by metformin's basal insulin sensitisation; combination reduced HbA1c by 1.4% and fasting glucose by 40 mg/dL. 15

Why is Metformin Cardio-Metabolic Benefit Unique and Long-Term?

The UKPDS 91 extended monitoring study confirmed that for up to 24 years after trial closure, the metformin legacy effect showed no sign of waning; patients originally randomised to intensive metformin therapy maintained a 20% relative risk reduction in all-cause mortality and a 31% reduction in myocardial infarction compared with conventional control, despite glycaemic control equalising within one year of the original trial ending. This durability is mechanistically rooted in metformin's persistent suppression of hepatic glucose output and amelioration of insulin resistance through hepatic AMPK activation, complementary benefits that continue irrespective of subsequent regimen intensification. 16

What are the Safety Considerations with Metformin?

• eGFR thresholds: Contraindicated if eGFR <30 mL/min/1.73 m²; reduce to ≤1,000 mg if eGFR 30–44 mL/min/1.73 m²; monitor renal function every 3–6 months in Indian practice where eGFR screening is often skipped. 17
• Iodinated contrast: For eGFR <30 mL/min/1.73 m², withhold 48 hours prior to imaging and restart only after renal function is reconfirmed stable, particularly relevant given high cardiac catheterisation volumes in India. 18
• Peri-operative management: Withhold on the day of major surgery; resume once oral intake normalises and renal function returns to baseline within 24–48 hours. 19

Figure 1: Metformin Anchoring Potential in T2D-Backbone numbers

Metformin's Brain-to-Body Glucose Control: April 2026 Research Spotlight Emerging evidence reveals that metformin crosses the blood-brain barrier and engages ventromedial hypothalamus SF1 neurons via Rap1 inhibition, a central glucose-lowering mechanism unique to metformin, not established by other approved antidiabetic agents at this time. This brain-directed pathway operates alongside peripheral hepatic AMPK suppression, offering a dual-axis explanation for metformin's enduring glycaemic efficacy in complex regimens. 20

Metformin - Quick Take in 2026

• Metformin remains the anchor of T2DM therapy for over six decades
• Backed by all major diabetes guidelines for >20 years.
• Pairs effectively as monotherapy & with almost every major glucose-lowering medication class.
• Provides cardiovascular protection.
• Acts through central glucose-regulating pathways as established in 2026, complementing peripheral actions.

Expert Perspective

In an era of rapidly expanding diabetes therapeutics, metformin continues to distinguish itself through evolving evidence; serving not only as a relevant first-line agent but also as the metabolic anchor that enhances the efficacy, safety, and long-term outcomes of contemporary combination therapies.

Practice Takeaways

• For over six decades, metformin has remained the cornerstone of T2DM management, established through cumulative clinical evidence as the therapeutic backbone in monotherapy and combination regimens.
• From cardiorenal synergy to central hypothalamic glucose regulation, metformin anchors as monotherapy and with multiple classes of glucose-lowering agents through complementary mechanisms supported by robust evidence and real-world clinical experience, forming an integral component of the metabolic journey of the T2D care continuum

Abbreviations: Abbreviations, ADA: American Diabetes Association, AACE: American Association of Clinical Endocrinology, AGIs: alpha-glucosidase inhibitors, AMPK: AMP-activated protein kinase, ASCVD: atherosclerotic cardiovascular disease, CKD: chronic kidney disease, CNS: central nervous systemDPP-4i: dipeptidyl peptidase-4 , inhibitor, eGFR: estimated glomerular filtration rate, GLP-1: glucagon-like peptide-1, GLP-1 RA: glucagon-like peptide-1 receptor agonist, mGIP: glucose-dependent insulinotropic polypeptide, HbA1c: glycated haemoglobin, HF: heart failure, PPG: postprandial glucose, Rap1: Ras-proximate-1, RSSDI: Research Society for the Study of Diabetes in India, SF1: steroidogenic factor 1, SGLT2i: sodium-glucose cotransporter-2 inhibitor, T2DM: type 2 diabetes mellitus, UKPDS: United Kingdom Prospective Diabetes Study, VMH: ventromedial hypothalamus